Skip to main content
Signal8
Launch Terminal

Kodiak Sciences Inc. (KOD)

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

NASDAQ:KODHealthcare
-1.22%$99.18
AH$99.99+0.82%vs close
Mkt Cap$6.23B
Float29.6M
O/S62.85M
Vol
$ Vol
RVOL
Inst Own96.4%
SI28.7%
Earnings
Dilution
Kodiak Sciences Inc. logoNASDAQ:KOD$99.18-1.22%
Phase Distribution
12 lead-sponsored trials·4 active·3 completed
Phase 11
Phase 2/31
Phase 310
Status Overview
Recruiting3
Active, not recruiting1
Completed3
Stopped5

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

    KSI-301, Aflibercept

    Macular Edema, Retinal Vein Occlusion

    Enrollment
    568
    Start
    Sep 2020
    Primary Completion
    Jun 2022
    Completion
    Jan 2023
    NCT04592419
  • Phase 3
    Terminated

    A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

    KSI-301, Aflibercept

    Diabetic Macular Edema

    Enrollment
    459
    Start
    Sep 2020
    Primary Completion
    Apr 2023
    Completion
    Aug 2023
    NCT04603937
  • Phase 3
    Terminated

    A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

    KSI-301, Aflibercept

    Diabetic Macular Edema

    Enrollment
    460
    Start
    Sep 2020
    Primary Completion
    May 2023
    Completion
    Aug 2023
    NCT04611152
  • Phase 3
    Completed

    A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

    KSI-301, Aflibercept

    Wet Age-related Macular Degeneration

    Enrollment
    557
    Start
    Jun 2021
    Primary Completion
    Mar 2023
    Completion
    Apr 2023
    NCT04964089
  • Phase 3
    Terminated

    A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

    KSI-301

    Non-proliferative Diabetic Retinopathy

    Enrollment
    253
    Start
    Sep 2021
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT05066230
  • Phase 3
    Completed

    A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

    Tarcocimab

    Diabetic Retinopathy

    Enrollment
    255
    Start
    May 2024
    Primary Completion
    Feb 2026
    Completion
    Feb 2026
    NCT06270836
  • Phase 3
    Active, not recruiting

    A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

    Tarcocimab tedromer, Tabirafusp tedromer

    Wet Age-related Macular Degeneration

    Enrollment
    675
    Start
    Aug 2024
    Primary Completion
    Aug 2026est.
    Completion
    Aug 2027est.
    NCT06556368
  • Phase 3
    Recruiting

    A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

    KSI-101

    Macular Edema Secondary to Inflammation

    Enrollment
    600
    Start
    Jul 2025
    Primary Completion
    Apr 2027est.
    Completion
    Nov 2027est.
    NCT06990399
  • Phase 3
    Recruiting

    A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

    KSI-101

    Macular Edema Secondary to Inflammation

    Enrollment
    300
    Start
    Jul 2025
    Primary Completion
    Feb 2027est.
    Completion
    Aug 2027est.
    NCT06996080
  • Phase 3
    Recruiting

    A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

    Tabirafusp tedromer, Aflibercept (2.0 mg)

    Diabetic Macular Edema (DME)

    Enrollment
    910
    Start
    Aug 2026
    Primary Completion
    Aug 2028est.
    Completion
    Sep 2029est.
    NCT07734844
  • Phase 2/3
    Terminated

    A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

    KSI-301, Aflibercept

    Wet Macular Degeneration

    Enrollment
    559
    Start
    Oct 2019
    Primary Completion
    Nov 2021
    Completion
    Apr 2022
    NCT04049266
  • Phase 1
    Terminated

    Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

    KSI-301

    Wet Age-related Macular Degeneration, Retinal Vein Occlusion +1

    Enrollment
    121
    Start
    Dec 2018
    Primary Completion
    Jun 2021
    Completion
    Jun 2022
    NCT03790852
Search ClinicalTrials.gov for “Kodiak Sciences”